Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2021 06:30 ET | Source: Avenue Therapeutics

Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol

NEW YORK, April 13, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
December 18, 2020 08:00 ET | Source: Avenue Therapeutics

Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced...
December 18, 2020 08:00 ET | Source: Avenue Therapeutics

Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced...
December 17, 2020 07:00 ET | Source: Avenue Therapeutics

Avenue Therapeutics Provides Regulatory Update for IV Tramadol

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today provided a...
October 12, 2020 06:30 ET | Source: Avenue Therapeutics

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
September 09, 2020 08:00 ET | Source: Avenue Therapeutics

Avenue Therapeutics Announces Publication of a Review of IV Tramadol

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
August 14, 2020 07:30 ET | Source: Avenue Therapeutics

Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
July 21, 2020 08:30 ET | Source: Avenue Therapeutics

Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results

NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
June 05, 2020 08:30 ET | Source: Avenue Therapeutics

Avenue Therapeutics Announces Publications in Peer-Reviewed Journals

NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
May 29, 2020 08:30 ET | Source: Avenue Therapeutics

Avenue Therapeutics to Host Virtual Annual Meeting of Stockholders

NEW YORK, May 29, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right